Biotech investors will get an infusion of good news beginning this weekend when researchers gather in San Diego to hear about new blood cancer drugs, Bill Alpert writes in this week’s edition of Barron’s. The annual meeting of the American Society of Hematology, or ASH, will feature developments from big companies like Celgene (CELG) and Amgen (AMGN), as well as up-and-comers like Bluebird Bio (BLUE) and Genmab (GNMSF), the report notes, adding that there will be early results of gene therapies and news on the fight against a hard-to-beat cancer called multiple myeloma.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.